Skip to content
Urelumab
Urelumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 9.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8043———4
Urologic neoplasmsD014571C64-C68—1———1
Urinary bladder neoplasmsD001749C67—1———1
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
LeukemiaD007938C95—1———1
MelanomaD008545—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151791————1
Head and neck neoplasmsD0062581————1
Multiple myelomaD009101C90.01————1
Non-small-cell lung carcinomaD0022891————1
Non-hodgkin lymphomaD008228C85.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameURELUMAB
INNurelumab
Description
Urelumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)URELUMAB
Structure (InChI/SMILES or Protein Sequence)
>6MHR:D,A|Urelumab Fab heavy chain QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSL KLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCAAAHHHHHHHH >6MHR:E,B|Urelumab Fab kappa chain EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP EDFAVYYCQQRSNWPPALTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >6MHR:F,C|Tumor necrosis factor receptor superfamily member 9 QDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQ DCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPENLYFQ
Identifiers
PDB6MHR
CAS-ID934823-49-1
RxCUI—
ChEMBL IDCHEMBL1743085
ChEBI ID—
PubChem CID—
DrugBankDB12077
UNII ID230902QLLC (ChemIDplus, GSRS)
Target
Agency Approved
TNFRSF9
TNFRSF9
Organism
Homo sapiens
Gene name
TNFRSF9
Gene synonyms
CD137, ILA
NCBI Gene ID
3604
Protein name
tumor necrosis factor receptor superfamily member 9
Protein synonyms
4-1BB ligand receptor, CD137, CD137 antigen, CDw137, homolog of mouse 4-1BB, induced by lymphocyte activation (ILA), interleukin-activated receptor, homolog of mouse Ly63, receptor protein 4-1BB, T cell antigen ILA, T-cell antigen 4-1BB homolog, T-cell antigen ILA
Uniprot ID
Q07011
Mouse ortholog
Tnfrsf9 (21942)
tumor necrosis factor receptor superfamily member 9 (P20334)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 587 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details